Page last updated: 2024-11-05

isovanillic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isovanillic acid, also known as 4-hydroxy-3-methoxybenzoic acid, is a naturally occurring phenolic compound found in various plants. It is a white crystalline solid with a melting point of 250-252 °C. Synthesis of isovanillic acid can be achieved through various methods, including oxidation of vanillin, a common flavoring agent, or via the Kolbe-Schmitt reaction. Isovanillic acid exhibits various biological activities, including antioxidant, anti-inflammatory, and anticancer properties. These properties have made it a subject of interest for researchers exploring its potential therapeutic applications. Additionally, isovanillic acid is involved in plant defense mechanisms, acting as a phytoalexin and protecting against pathogens. Its role in plant metabolism and its potential as a natural therapeutic agent continue to drive ongoing research in various fields.'

3-hydroxy-4-methoxybenzoic acid : A methoxybenzoic acid that is 4-methoxybenzoic acid bearing a hydroxy substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12575
CHEMBL ID88700
CHEBI ID63798
SCHEMBL ID180473
MeSH IDM0131854

Synonyms (43)

Synonym
CHEMBL88700 ,
chebi:63798 ,
acide isovanillique
einecs 211-430-5
p-anisic acid, 3-hydroxy-
3-hydroxyanisic acid
3-hydroxy-p-anisic acid
brn 2208365
benzoic acid, 3-hydroxy-4-methoxy-
BB 0262336
3-hydroxy-4-methoxybenzoic acid
isovanillic acid
inchi=1/c8h8o4/c1-12-7-3-2-5(8(10)11)4-6(7)9/h2-4,9h,1h3,(h,10,11
isovanillic acid, 97%
AC-2478
AKOS000277443
645-08-9
I0295
bdbm50405313
a8d1dux2pr ,
unii-a8d1dux2pr
FT-0615822
STL372962
AM20060454
S5162
BBL027386
SCHEMBL180473
SY001558
mfcd00002507
3-hydroxy-4-methoxy benzoic acid
3-hydroxy-4-(methyloxy)benzoic acid
3-hydroxy-4-methoxy-benzoic acid
3-hydroxyl-4-methoxybenzoic acid
W-104831
DTXSID40214745
GS-3245
74309-78-7
Q1674563
EN300-99197
HY-N6864
CS-W014300
CCG-266344
Z381356676
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
methoxybenzoic acidAny benzoic acid carrying one or more methoxy substituents.
monohydroxybenzoic acidAny hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Vanillin and isovanillin metabolism04

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)100.00000.03403.987110.0000AID1059453
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
methylationThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic catabolic processThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingThiopurine S-methyltransferaseHomo sapiens (human)
thiopurine S-methyltransferase activityThiopurine S-methyltransferaseHomo sapiens (human)
S-adenosyl-L-methionine bindingThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID336478Inhibition of COX2 at 100 uM by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID1059453Inhibition of mushroom tyrosinase using L-tyrosine as substrate preincubated for 10 mins followed by enzyme addition measured after 20 mins by microplate reader analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis, antioxidant capacity, and structure-activity relationships of tri-O-methylnorbergenin analogues on tyrosinase inhibition.
AID49927Ability to inhibit Catechol O-methyltransferase from rat liver at a concentration of 1 mM. Inhibition pattern was reported; No inhibitory activity1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors.
AID293934Inhibition of pieris rapae Phenoloxidase2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
AID338335Antiplatelet activity against rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.25 mg/ml pretreated 2 mins before arachidonic acid challenge
AID1059449Inhibition of mushroom tyrosinase using L-tyrosine as substrate at 100 uM preincubated for 10 mins followed by enzyme addition measured after 20 mins by microplate reader analysis relative to control2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis, antioxidant capacity, and structure-activity relationships of tri-O-methylnorbergenin analogues on tyrosinase inhibition.
AID1059454Antioxidant activity assessed as trolox equivalent of APPH-induced peroxyl radical scavenging activity at 5 to 20 uM measured every 1 min for 120 mins by ORAC fluorescence assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis, antioxidant capacity, and structure-activity relationships of tri-O-methylnorbergenin analogues on tyrosinase inhibition.
AID1090826Antifeedant activity against Hylobius abietis (pine weevil ) in compound pre-treated Scots pine twig at 50 mM measured after 24 hr by two-choice laboratory bioassay2007Journal of agricultural and food chemistry, Nov-14, Volume: 55, Issue:23
Quantitative structure-activity relationships of pine weevil antifeedants, a multivariate approach.
AID1102544Inhibition of tyrosinase activity in Oryza sativa Indica (rice) bran using L-tyrosine as substrate at 0.5 umol/ml after 60 min by spectrophotometric analysis2003Journal of agricultural and food chemistry, Nov-19, Volume: 51, Issue:24
Tyrosinase inhibitor from black rice bran.
AID338339Antiplatelet activity against rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 1 mg/ml pretreated 2 mins before ADP challenge
AID213093Inhibition of purified human kidney thiopurine methyltransferase (TPMT)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.
AID338333Antiplatelet activity against rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.5 mg/ml pretreated 2 mins before arachidonic acid challenge
AID1239713Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 100 uM pre-incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Potential therapeutic agents for circulatory diseases from Bauhinia glauca Benth.subsp. pernervosa. (Da Ye Guan Men).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (12.00)18.7374
1990's4 (16.00)18.2507
2000's9 (36.00)29.6817
2010's8 (32.00)24.3611
2020's1 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.14 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]